三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
表14Protyouth旗下五项产品获得FDA及SFDA双认证
表14Protyouth旗下五项产品获得FDA及SFDA双认证
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:1199KB
图片尺寸:1735*1533
同报告图片
/
4
fCDooagxNCB8IFByb3R5b3V0aOaXl+S4i+S6lOmhueS6p+WTgeiOt+W+l0ZEQeWPilNGREHlj4zorqTor4EgfCAKfC0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfCAKfCDkuqflk4HlkI3np7AgfCDorqTor4HmnLrmnoQgfCDorqTor4HnvJblj7cgfCDorqTor4Hml6XmnJ8gfCAKfCBQcm90eW91dGjmtIHpnaLkubMgfCBGREEgfCAxMjM0NTY3ODkgfCAyMDIxLTAxLTAxIHwgCnwgUHJvdHlvdXRo54i96IKk5rC0IHwgRkRBIHwgMTIzNDU2NzkwIHwgMjAyMS0wMi0wMSB8IAp8IFByb3R5b3V0aOeyvuWNjua2siB8IEZEQSB8IDEyMzQ1Njc5MSB8IDIwMjEtMDMtMDEgfCAKfCBQcm90eW91dGjpnaLpnJwgfCBGREEgfCAxMjM0NTY3OTIgfCAyMDIxLTA0LTAxIHwgCnwgUHJvdHlvdXRo55y86ZycIHwgRkRBIHwgMTIzNDU2NzkzIHwgMjAyMS0wNS0wMSB8IAp8IFByb3R5b3V0aOa0gemdouS5syB8IFNGREEgfCAxMjM0NTY3OTQgfCAyMDIxLTA2LTAxIHwgCnwgUHJvdHlvdXRo54i96IKk5rC0IHwgU0ZEQSB8IDEyMzQ1Njc5NSB8IDIwMjEtMDctMDEgfCAKfCBQcm90eW91dGjnsr7ljY7mtrIgfCBTRkRBIHwgMTIzNDU2Nzk2IHwgMjAyMS0wOC0wMSB8IAp8IFByb3R5b3V0aOmdoumcnCB8IFNGREEgfCAxMjM0NTY3OTcgfCAyMDIxLTA5LTAxIHwgCnwgUHJvdHlvdXRo55y86ZycIHwgU0ZEQSB8IDEyMzQ1Njc5OCB8IDIwMjEtMTAtMDEgfCAKCui1hOaWmeadpea6kO+8mumUpuazoueUn+eJqeWFrOS8l+WPt++8jEhUSeaVtOeQhg==
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
所属报告:
锦波生物(832982)-A股公司首次覆盖:三张重组胶原蛋白械三证书护航国内外布局双驱动力推进市场前景广阔-250725(51页).pdf
打包全文图表
相关数据
到2040年美国FDA批准的中国原创新药占比
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
收藏
行业数据
2026-06-11
原图定位
查看详情
美国FDA各年度批准NME药物与生物药数量
收藏
行业数据
2026-05-25
原图定位
查看详情
美国FDA药物评价与研究中心受理的IND申请
收藏
行业数据
2026-04-08
原图定位
查看详情
图表11FDA获批KRASG12C抑制剂的全球销售额(百万美元)
收藏
行业数据
2026-02-25
原图定位
查看详情
图 26 美国食品和药物管理局(FDA)在2020年开始实施RACE法案,以确保更多癌症药物试验包括儿童人群
收藏
行业数据
2026-02-13
原图定位
查看详情
**TABLE 5. FDA-approved Immunotherapeutics to Treat Pediatric Cancers (2015–2025)**
收藏
行业数据
2026-02-13
原图定位
查看详情
**TABLE 4 FDA-approved Molecularly Targeted Therapies to Treat Pediatric Cancers (2015–2025)**
收藏
行业数据
2026-02-13
原图定位
查看详情
表 5 FDA批准的免疫治疗药物用于治疗儿科癌症(2015–2025)
收藏
行业数据
2026-02-13
原图定位
查看详情
Figure 2 FDA-approved therapeutics with CDx, including novel oncological therapies (1997-2024)
收藏
行业数据
2026-02-13
原图定位
查看详情
表4 FDA批准的分子靶向疗法用于治疗儿童癌症(2015–2025)
收藏
行业数据
2026-02-13
原图定位
查看详情
2018-2024年FDA批准的创新抗体药物分类(个)
fCDliIbnsbsgICB8IOaVsOmHj++8iOS4qu+8iSB8IOWNoOavlCAgIHwKfCAtLS0tLS0gfCAtLS0tLS0tLS0tIHwgLS0tLS0tIHwKfCDltYzlkIjkvZMgfCAzICAgICAgICAgIHwgNC42JSAgIHwKfCDlhajkurrmupAgfCAyMiAgICAgICAgIHwgMzMuOCUgIHwKfCDkurrmupDljJYgfCA0MCAgICAgICAgIHwgNjEuNSUgIHwKCui1hOaWmeadpea6kO+8muWFrOWPuOaLm+iCoeS5pu+8jOW8l+iLpeaWr+eJueaymeWIqeaWh++8jOWbveazsOa1t+mAmuivgeWIuOeglOeptg==
收藏
行业数据
2026-01-27
原图定位
查看详情
2018-2024年FDA批准的全人源抗体制备技术分
fCDmioDmnK/nsbvliKsgICAgICAgfCDmlbDph4/vvIjkuKrvvIkgfAp8LS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS18Cnwg6L2s5Z+65Zug5bCP6byg5oqA5pyvIHwgOSAgICAgICAgICB8Cnwg5Zms6I+M5L2T5bGV56S65oqA5pyvIHwgNyAgICAgICAgICB8Cnwg5YW25a6D5oqA5pyvICAgICAgIHwgNiAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrlhazlj7jmi5vogqHkuabvvIzlvJfoi6Xmlq/nibnmspnliKnmlofvvIzlm73ms7DmtbfpgJror4HliLjnoJTnqbY=
收藏
行业数据
2026-01-27
原图定位
查看详情
FDA拟禁用合成色素种类在欧盟和中国使用情况
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
收藏
行业数据
2026-01-15
原图定位
查看详情
2018-2024各年NMPA及FDA合批准的抗
fCDlubTku70gfCDmipfkvZPoja/mlbDph4/vvIjkuKrvvIkgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwKfCAyMDE4IHwgMjAgICAgICAgICAgICAgICB8CnwgMjAxOSB8IDE2ICAgICAgICAgICAgICAgfAp8IDIwMjAgfCAxNiAgICAgICAgICAgICAgIHwKfCAyMDIxIHwgMjEgICAgICAgICAgICAgICB8CnwgMjAyMiB8IDIxICAgICAgICAgICAgICAgfAp8IDIwMjMgfCAyMyAgICAgICAgICAgICAgIHwKfCAyMDI0IHwgMzIgICAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrnmb7lpaXotZvlm77mi5vogqHkuabvvIxGREHvvIxDREXvvIzlvJfoi6Xmlq/nibnmspnliKnmlofvvIzlm73ogZTmsJHnlJ/or4HliLg=
收藏
行业数据
2026-01-05
原图定位
查看详情
2018-2024FDA批准的创新抗体药分类
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
收藏
行业数据
2026-01-05
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
锦波生物功能性护肤品出海方面,5 项产品获得 FDA 和 SFDA 双认证。2025 年 1 月,公司宣布 Protyouth 旗下上述三款主要产品(T8 分子、T16 分子和高浓度 III 型胶原+高浓度 XVII 型胶原)及另外两款产品(胶原多肽精华液和三重胶原蛋白面霜)均通过美国 FDA 认证。2025 年 5 月公司再次宣布 ProtYouh 3 款产品胶原多肽精华液、奢宠双胶原原液(高浓度 III 型胶原+高浓度 XVII 型胶原)、三重胶原蛋白面霜成功完成 SFDA(沙特阿拉伯食品药品监督局)备案;2025 年 6 月,公司再次宣布 T8、T16 获得成功完成 SFDA 备案,是继此前获得美国 FDA 认证后,五款产品的"双证通关"。
行业数据
原图定位
当前图表所属:
锦波生物(832982)-A股公司首次覆盖:三张重组胶原蛋白械三证书护航国内外布局双驱动力推进市场前景广阔-250725(51页).pdf
4mg/10mg/12mg
表9国家药监局通过一系列重组胶原蛋白行业相关法规和标准
表8里宾斯基五规则
双美、弗缦
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》